Page 2 - Side Effect Management News Today

There were certain characteristics associated with a perceived loss of dignity in patients with cancer, according to recent research.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.

Robert Mancini, PharmD, discusses bispecific therapy advancements and strategies to manage adverse effects in diffuse large B-cell lymphoma (DLBCL) care, offering insights on toxicity phases, monitoring, and patient care.

A cancer-related side effect I faced was constipation caused by pain medication.

Panelists explore the challenges, implementations, and decision-making processes surrounding bispecific treatments in DLBCL (diffuse large B cell lymphoma).

Health care experts provide insights into patient education, shared decision-making, and treatment monitoring in DLBCL (diffuse large B cell lymphoma) therapies, reviewing education strategies and response monitoring.

Children with cancer tended to feel less anxiety after undergoing four sessions of creative art therapy, recent research showed.

Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.

The FDA granted an orphan drug designation for the novel drug, NT-17, to treat people with acute radiation syndrome.

Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.